291 related articles for article (PubMed ID: 24504791)
1. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.
Bass JK; Huang J; Onar-Thomas A; Chang KW; Bhagat SP; Chintagumpala M; Bartels U; Gururangan S; Hassall T; Heath JA; McCowage G; Cohn RJ; Fisher MJ; Robinson G; Broniscer A; Gajjar A; Gurney JG
Pediatr Blood Cancer; 2014 Apr; 61(4):601-5. PubMed ID: 24504791
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy.
Clemens E; Brooks B; de Vries ACH; van Grotel M; van den Heuvel-Eibrink MM; Carleton B
PLoS One; 2019; 14(2):e0210646. PubMed ID: 30763334
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.
Gurney JG; Bass JK; Onar-Thomas A; Huang J; Chintagumpala M; Bouffet E; Hassall T; Gururangan S; Heath JA; Kellie S; Cohn R; Fisher MJ; Panandiker AP; Merchant TE; Srinivasan A; Wetmore C; Qaddoumi I; Stewart CF; Armstrong GT; Broniscer A; Gajjar A
Neuro Oncol; 2014 Jun; 16(6):848-55. PubMed ID: 24414535
[TBL] [Abstract][Full Text] [Related]
4. Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group.
Knight KR; Chen L; Freyer D; Aplenc R; Bancroft M; Bliss B; Dang H; Gillmeister B; Hendershot E; Kraemer DF; Lindenfeld L; Meza J; Neuwelt EA; Pollock BH; Sung L
J Clin Oncol; 2017 Feb; 35(4):440-445. PubMed ID: 27937095
[TBL] [Abstract][Full Text] [Related]
5. Applications of the Grading Scales for the Detection of Ototoxicity in Children after Treatment of Neuroblastoma and Extracranial Germinal Tumor.
Polski B; Sosnowska-Sienkiewicz P; Szydłowski J; Januszkiewicz-Lewandowska D
Audiol Neurootol; 2023; 28(1):32-42. PubMed ID: 36191558
[TBL] [Abstract][Full Text] [Related]
6. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group.
Landier W; Knight K; Wong FL; Lee J; Thomas O; Kim H; Kreissman SG; Schmidt ML; Chen L; London WB; Gurney JG; Bhatia S
J Clin Oncol; 2014 Feb; 32(6):527-34. PubMed ID: 24419114
[TBL] [Abstract][Full Text] [Related]
7. Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma.
Lafay-Cousin L; Purdy E; Huang A; Cushing SL; Papaioannou V; Nettel-Aguirre A; Bouffet E
Pediatr Blood Cancer; 2013 Feb; 60(2):287-92. PubMed ID: 23002030
[TBL] [Abstract][Full Text] [Related]
8. SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma.
Brown AL; Lupo PJ; Okcu MF; Lau CC; Rednam S; Scheurer ME
Cancer Med; 2015 Nov; 4(11):1679-86. PubMed ID: 26400460
[TBL] [Abstract][Full Text] [Related]
9. Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin.
Colevas AD; Lira RR; Colevas EA; Lavori PW; Chan C; Shultz DB; Chang KW
Head Neck; 2015 Aug; 37(8):1102-7. PubMed ID: 24737682
[TBL] [Abstract][Full Text] [Related]
10. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.
Fouladi M; Chintagumpala M; Ashley D; Kellie S; Gururangan S; Hassall T; Gronewold L; Stewart CF; Wallace D; Broniscer A; Hale GA; Kasow KA; Merchant TE; Morris B; Krasin M; Kun LE; Boyett JM; Gajjar A
J Clin Oncol; 2008 Aug; 26(22):3749-55. PubMed ID: 18669462
[TBL] [Abstract][Full Text] [Related]
11. Ototoxicity evaluation in medulloblastoma patients treated with involved field boost using intensity-modulated radiation therapy (IMRT): a retrospective review.
Vieira WA; Weltman E; Chen MJ; da Silva NS; Cappellano AM; Pereira LD; Gonçalves MI; Ferrigno R; Hanriot RM; Nadalin W; Odone Filho V; Petrilli AS
Radiat Oncol; 2014 Jul; 9():158. PubMed ID: 25041714
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation of a novel PAK4 locus influences ototoxicity susceptibility following cisplatin and radiation therapy for pediatric embryonal tumors.
Brown AL; Foster KL; Lupo PJ; Peckham-Gregory EC; Murray JC; Okcu MF; Lau CC; Rednam SP; Chintagumpala M; Scheurer ME
Neuro Oncol; 2017 Oct; 19(10):1372-1379. PubMed ID: 28444219
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma.
Musial-Bright L; Fengler R; Henze G; Hernáiz Driever P
Childs Nerv Syst; 2011 Mar; 27(3):407-13. PubMed ID: 20931205
[TBL] [Abstract][Full Text] [Related]
14. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
15. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
Peleva E; Emami N; Alzahrani M; Bezdjian A; Gurberg J; Carret AS; Daniel SJ
Pediatr Blood Cancer; 2014 Nov; 61(11):2012-7. PubMed ID: 24976616
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study.
Moke DJ; Luo C; Millstein J; Knight KR; Rassekh SR; Brooks B; Ross CJD; Wright M; Mena V; Rushing T; Esbenshade AJ; Carleton BC; Orgel E
Lancet Child Adolesc Health; 2021 Apr; 5(4):274-283. PubMed ID: 33581749
[TBL] [Abstract][Full Text] [Related]
17. Hearing Loss Risk in Pediatric Patients Treated with Cranial Irradiation and Cisplatin-Based Chemotherapy.
Cohen-Cutler S; Wong K; Mena V; Sianto K; Wright MA; Olch A; Orgel E
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1488-1495. PubMed ID: 33677052
[TBL] [Abstract][Full Text] [Related]
18. Practical grading system for evaluating cisplatin ototoxicity in children.
Chang KW; Chinosornvatana N
J Clin Oncol; 2010 Apr; 28(10):1788-95. PubMed ID: 20194861
[TBL] [Abstract][Full Text] [Related]
19. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
20. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity.
Huang E; Teh BS; Strother DR; Davis QG; Chiu JK; Lu HH; Carpenter LS; Mai WY; Chintagumpala MM; South M; Grant WH; Butler EB; Woo SY
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):599-605. PubMed ID: 11849779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
